efflux
pump
play
major
role
increas
antimicrobi
resist
render
larg
number
drug
use
larg
number
pathogen
becom
multidrug
resist
due
inadequ
dosag
use
exist
antimicrobi
lead
need
identifi
new
efflux
pump
inhibitor
design
novel
target
therapi
use
inher
complex
involv
biolog
network
model
gain
increas
import
recent
time
predict
approach
use
determin
antimicrobi
activ
high
pathogen
specif
microbicid
potenc
antimicrobi
peptid
part
innat
immun
system
abil
respond
infect
gain
much
attent
make
resist
strain
sensit
exist
drug
review
paper
outlin
evid
link
hostdirect
therapi
efflux
pump
activ
infecti
diseas
antimicrobi
resist
condit
microorgan
like
bacteria
fungi
virus
parasit
chang
expos
variou
antimicrobi
drug
way
drug
render
ineffect
drug
use
sinc
success
treat
variou
infect
longterm
usag
inadequ
dosag
frequenc
evolv
microb
result
develop
resist
drug
resist
organ
major
concern
present
world
difficult
treat
due
longer
durat
treatment
quit
expens
drug
infect
caus
resist
organ
may
also
result
relaps
diseas
disabl
death
sinc
new
resist
mechan
evolv
high
rate
cdcdrug
resist
nd
whoantimicrobi
resist
nd
mechan
resist
develop
may
broadli
classifi
three
categori
intrins
resist
acquir
resist
adapt
resist
intrins
resist
involv
mechan
intrins
microb
act
lower
concentr
drug
insid
cell
either
decreas
uptak
drug
extrus
efflux
pump
focus
variou
efflux
pump
brief
resist
result
mutat
horizont
gene
transfer
resist
gene
refer
acquir
resist
may
achiev
either
degrad
antimicrobi
drug
modifi
henc
protect
drug
target
case
antimicrobi
drug
may
interact
drug
protein
may
result
induct
gene
therebi
caus
resist
type
resist
name
adapt
resist
hugh
andersson
mechan
resist
mediat
efflux
pump
clinic
refer
signific
mode
resist
efflux
pump
transmembran
protein
present
ubiquit
plasma
membran
form
life
classifi
six
major
famili
fig
name
small
multidrug
resist
smr
superfamili
proteobacteri
antimicrobi
compound
efflux
pace
superfamili
major
facilit
superfamili
mf
multidrug
toxic
compound
extrus
mate
superfamili
resist
nodul
divis
rnd
famili
atp
adenosin
triphosph
bind
cassett
abc
superfamili
abc
efflux
pump
primari
activ
transport
util
atp
hydrolysi
energi
sourc
extrus
smr
pace
mate
mf
rnd
pump
act
secondari
activ
transport
sinc
use
proton
motiv
forc
pmf
sodium
ion
gradient
energi
sourc
munita
aria
spengler
amar
smr
transport
smallest
efflux
pump
amino
acid
length
four
transmembran
helic
tmh
gener
function
homodim
found
bacteria
archaeabacteria
smr
famili
protein
transport
lipophil
compound
varieti
antibiot
bay
et
al
spengler
amar
pace
famili
protein
commonli
found
proteobacteria
efflux
variou
synthet
biocid
like
chlorhexidin
dequalinium
benzalkonium
proflavin
acriflavin
etc
hassan
et
al
mf
efflux
pump
constitut
larg
famili
transport
ubiquit
express
kingdom
life
transport
divers
varieti
substrat
like
ion
oligosaccharid
amino
acid
small
metabolit
variou
antimicrobi
agent
protein
consist
tmh
group
two
six
helic
therebi
form
dimer
like
structur
length
amino
acid
residu
blanco
et
al
spengler
amar
mate
famili
multi
antimicrobi
extrus
protein
function
drugsodium
proton
antiport
found
bacteria
archaea
well
eukaryot
length
member
protein
famili
rang
amino
acid
residu
tmh
mate
transport
extrud
variou
antimicrobi
agent
like
norfloxacin
chloramphenicol
ciprofloxacin
kanamycin
ampicillin
metformin
cimetidin
ethidium
triethylammonium
kuroda
tsuchiya
rnd
efflux
pump
act
protondrug
antiport
exist
primarili
gram
neg
bacteria
although
also
found
gram
posit
bacteria
archaea
eukaryot
one
largest
superfamili
efflux
protein
primari
transport
atp
bind
cassett
abc
transport
protein
util
atp
hydrolysi
energi
sourc
abc
protein
also
known
orphan
protein
efflux
larg
rang
molecul
like
ion
phospholipid
small
molecul
antibiot
etc
spengler
amar
review
discuss
variou
strategi
use
fight
antimicrobi
resist
superbug
focus
efflux
pump
inhibitor
epi
amp
antimicrobi
peptid
use
target
efflux
pump
compound
rais
urgenc
develop
newer
strategi
fight
superbug
amongst
variou
strategi
one
promis
futur
target
efflux
pump
pump
target
either
increas
intracellular
concentr
antimicrobi
compound
efflux
make
superbug
sensit
exist
drug
achiev
modifi
improv
structur
antimicrobi
decreas
efflux
decreas
efficaci
membran
barrier
amount
antimicrobi
penetr
insid
cell
last
least
alloster
alteringblock
efflux
pump
function
mechan
action
variou
antimicrobi
shown
fig
detail
current
use
antimicrobi
resist
strain
given
tabl
vast
research
done
still
go
gener
resist
revers
compound
discuss
detail
abund
efflux
pump
bacteria
mf
rnd
pump
found
gramposit
gramneg
bacteria
spengler
amar
compar
gramneg
bacteria
prone
resist
presenc
larg
periplasm
space
along
outer
membran
drug
sequest
efflux
pump
directli
periplasm
extrud
even
reach
cytoplasm
mahamoud
et
al
nonapeptid
deriv
polymyxin
b
found
effect
test
erythromycinresist
klebsiella
pneumonia
peptid
conjug
act
increas
permeabl
bacteri
outer
membran
hydrophob
antibiot
tsuberi
et
al
compound
target
proton
motiv
forc
requir
function
efflux
pump
like
verapamil
reserpin
also
use
increas
efficaci
antibiot
major
disadvantag
use
compound
concentr
requir
effect
neurotox
even
chemic
synthes
deriv
compound
ineffect
due
stabil
solubl
issu
along
high
cost
purif
synthesi
li
et
al
mani
p
aeruginosa
resist
clinic
strain
abl
restor
levofloxacin
suscept
variou
structur
deriv
well
pyridopyrimidin
shown
promis
result
inhibit
efflux
pump
p
aeruginosa
invitro
condit
epi
efflux
pump
inhibitor
fail
clinic
trial
owe
toxic
mahamoud
et
al
screen
procedur
e
aerogen
strain
k
pneumonia
led
discoveri
new
class
epi
name
quinolin
deriv
compound
success
make
resist
strain
suscept
chloramphenicol
tetracyclin
norfloxacin
deriv
wide
varieti
side
chain
like
alkylamino
alkoxi
thioalkoxi
chloroquinolin
etc
show
promis
result
structureact
relationship
analysi
also
advantag
effici
pharmacokinet
profil
well
least
side
effect
permeabil
alter
membran
function
howev
pharmacodynam
cytotox
studi
along
invivo
studi
need
check
actual
therapeut
applic
compound
chevali
et
al
gallo
et
al
arylpiperidin
arylpiperazin
deriv
like
nmethylpyrrolidon
shown
resist
revers
effect
escherichia
coli
staphylococcu
aureu
acinetobact
baumannii
speci
enterobacteriacea
bohnert
kern
kern
et
al
pannek
et
al
apart
compound
new
emerg
class
antimicrobi
peptid
amp
includ
natur
occur
peptid
well
synthet
deriv
broad
spectrum
target
antibacteri
amp
amongst
studi
one
cation
amphipath
natur
therebi
easi
interact
lipid
bilay
henc
target
bacteri
cell
membran
nisin
amp
administ
ramoplanin
chloramphenicol
abl
restor
sensit
methicillin
resist
staphylococcu
aureu
mrsa
vancomycin
resist
enterococci
vre
howev
signific
investig
still
requir
reach
clinic
trial
bahar
ren
brumfitt
foremost
fungal
pathogen
affect
human
includ
speci
aspergillu
candida
cryptococcu
pfaller
diekema
compar
antibacteri
resist
antifung
resist
major
problem
immunocompromis
individu
lethal
efficaci
commonli
use
antifung
like
fluconazol
ketoconazol
itraconazol
voriconazol
benomyl
methotrex
etc
decreas
mostli
due
overexpress
efflux
pump
efflux
pump
respons
multidrug
resist
abc
mf
transport
saccharomyc
cerevisia
multidrug
resist
known
pleiotrop
drug
resist
pdr
best
understood
mechan
fungal
drug
resist
studi
abc
mf
transport
homologu
cerevisia
monk
goffeau
propafenon
terbinafin
found
effect
azol
resist
baker
yeast
well
strain
c
albican
schuetzermuehlbau
et
al
antifung
amp
belong
structur
class
like
alphahel
extend
well
betasheet
found
amp
like
indolicin
defensin
etc
mostli
target
fungal
cell
membran
effect
even
resist
fungal
cell
bahar
ren
tabl
detail
current
use
antimicrobi
agent
resist
strain
probabl
mechan
action
antimicrobi
agent
strain
probabl
mechan
refer
antibacteri
k
pneumonia
increas
permeabl
bacteri
outer
membran
tsuberi
et
al
inhibit
rnd
type
efflux
pump
bohnert
kern
inhibit
efflux
pump
mahamoud
et
al
quinolin
deriv
e
aerogen
k
pneumonia
inhibit
efflux
pump
chevali
et
al
arylpiperidin
arylpiperazin
inhibit
efflux
pump
bohnert
kern
kern
et
al
nisin
amp
cell
lysi
brumfitt
antifung
antiparasit
plasmodium
alkyl
biomolecul
oxid
stress
cellular
damag
blasco
et
al
amp
dermaseptin
cercopin
melettin
cathelicidin
magainin
c
elegan
p
caudatum
leishmania
disrupt
membran
integr
interrupt
protein
dna
rna
synthesi
etc
bahar
ren
hopkin
groom
mangoni
et
al
antivir
common
drug
resist
virus
cytomegaloviru
cmv
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
influenza
viru
varicella
zoster
viru
hepat
b
viru
hbv
tanwar
et
al
viral
strain
result
either
acquir
adapt
resist
room
intrins
resist
antivir
amp
act
either
caus
membran
instabl
reduct
hostviru
interact
mechan
util
defensin
amp
render
hsv
unabl
bind
host
cell
yasin
et
al
antivir
amp
like
lactoferrin
prevent
hsv
infect
block
virusreceptor
interact
jenssen
et
al
recent
studi
research
group
discov
nonpeptid
small
molecul
cyclophilin
inhibitor
potent
antivir
activ
hepat
c
viru
hiv
coronavirus
ahmedbelkacem
et
al
per
who
recent
report
malaria
stand
race
largest
parasit
killer
close
follow
leishmaniasi
first
report
resist
antimalari
drug
quinin
chloroquin
report
back
earli
combinatori
therapi
came
exist
involv
proguanil
atovaquon
sulfadoxin
e
pyrimethamin
napthoquinon
atremisinin
etc
sooner
later
plasmodium
show
resist
current
first
line
defens
use
artemisinin
base
combinatori
therapi
instanc
resist
artemisinin
combinatori
therapi
show
partner
drug
respons
candid
blasco
et
al
taylor
juliano
leishmania
one
neglect
microb
caus
leishmaniasi
endem
countri
across
globe
mani
strain
parasit
found
resist
recommend
drug
like
antimoni
miltefosin
amphotericin
b
pentamidin
paromomycin
sitamaquin
etc
one
major
caus
develop
resist
drug
irregular
inappropri
use
endem
region
singh
et
al
variou
invitro
experi
suggest
drug
resist
strain
l
donovani
show
decreas
accumul
miltefosin
effect
may
due
involv
either
abc
transport
protein
pglycoprotein
pgp
may
increas
drug
efflux
decrement
drug
uptak
organ
contribut
two
protein
miltefosin
transport
ldmt
beta
subunit
perezvictoria
et
al
larg
number
abc
transport
identifi
far
protein
belong
three
subfamili
multi
drug
resist
pglycoprotein
pgp
multidrug
resist
associ
protein
breast
cancer
resist
protein
brcp
believ
play
import
role
drug
efflux
henc
multidrug
resist
phenomenon
ferreira
et
al
abc
transport
pgp
consist
four
domain
two
transmembran
domain
tmd
two
nucleotidebind
domain
nbd
arrang
head
tail
fashion
tmd
consist
helic
capabl
recogn
wide
varieti
substrat
nbd
consist
larger
catalyt
sub
domain
smaller
domain
walker
motif
gxxgxgkst
walker
b
motif
ffffd
part
domain
smaller
helic
domain
conserv
abc
signatur
motif
cmotif
lsggq
dawson
locher
order
combat
resist
strain
variou
combinatori
therapi
use
due
increas
drug
select
reduc
toxic
compat
target
protein
structur
amp
exampl
dermaseptin
cecropin
melettin
etc
describ
first
line
defens
pathogen
invas
includ
protozoa
hopkin
groom
lynn
et
al
mangoni
et
al
marr
et
al
toro
et
al
ruizsantaquiteria
et
al
intens
investig
improv
druggabl
mode
action
involv
perturb
protozoan
homeostasi
directli
disrupt
cellular
membran
interact
interfer
key
process
parasit
metabol
afacan
et
al
jenssen
et
al
torrent
et
al
variou
experiment
comput
platform
propos
develop
effici
amp
fjell
et
al
hilpert
et
al
lata
et
al
torrent
et
al
torrent
et
al
wang
synthet
amp
also
design
found
effect
treat
canin
leishmaniasi
alberola
et
al
success
restrict
invitro
condit
none
succeed
invivo
clinic
trial
besid
antimicrobi
role
amp
also
involv
chemotaxi
redox
homeostasi
rapid
radic
scaveng
abil
cole
et
al
com
et
al
ganz
liu
et
al
zhao
et
al
recent
metagenom
approach
extens
review
explor
role
amp
redox
homeostasi
champion
xu
nifurtimox
benznidazol
use
trypanosoma
cruzi
show
mani
side
effect
patient
melarsoprol
use
trypanosoma
brucei
may
lethal
chronic
case
past
decad
sudden
increas
case
resist
schistosoma
praziquantel
acevedo
et
al
peptid
like
magainin
paramecium
caudatum
cathelicidin
caenorhabd
elegan
design
bahar
ren
efficaci
drug
decreas
result
emerg
resist
also
toxic
effect
make
unsuit
use
rais
urgenc
find
altern
decreas
revers
resist
condit
make
microb
sensit
exist
drug
due
exponenti
increas
size
biolog
data
develop
advanc
system
biolog
integr
mathemat
method
comput
approach
recent
much
interest
system
biolog
approach
util
model
variou
pathway
system
studi
dynam
combin
metabol
network
beit
roo
pillay
et
al
omic
data
go
et
al
strategi
impli
find
novel
therapeut
target
systemsbas
applic
metabolom
larg
scale
analysi
small
molecul
provid
import
insight
metabol
process
barrett
et
al
creek
et
al
kafsack
llina
lakshmanan
et
al
saunder
et
al
scheltema
et
al
swann
et
al
anoth
strategi
combat
resist
target
redox
metabol
pathway
microb
identif
novel
target
use
system
biolog
approach
fig
although
host
provid
surviv
advantag
parasit
offer
unlimit
nutrit
suppli
environment
chang
also
entail
potenti
risk
host
defens
parasit
undergo
tremend
oxid
stress
neutral
surviv
mainten
redox
homeostasi
princip
import
parasit
redox
metabol
gain
greater
interest
due
distinct
redox
system
comparison
host
salina
applic
metabolom
analysi
understand
respons
oxid
stress
e
histolytica
studi
expos
trophozoit
variou
reactiv
oxygen
nitrogen
speci
ro
rn
jeelani
nozaki
vicent
et
al
husain
et
al
studi
reveal
oxid
stress
affect
level
metabolit
synthesi
inactiv
sever
key
enzym
involv
glycolysi
associ
pathway
h
mediat
oxid
stress
help
identif
indispens
role
cystein
synthas
cs
serin
acetyltransferas
sat
enzym
involv
cystein
synthesi
pathway
e
histolytica
trophozoit
surviv
growth
attach
elong
motil
gene
regul
oxid
stress
defens
fahey
et
al
gillin
diamond
husain
et
al
jeelani
et
al
jeelani
nozaki
jeelani
et
al
import
cystein
also
studi
trypanosoma
cruzi
epimastigot
transit
exponenti
stationari
growth
phase
bari
et
al
observ
de
novo
cystein
synthesi
pathway
increas
stationari
phase
reveal
crucial
metabol
switch
mechan
cope
phase
transit
environ
chang
exponenti
stationari
growth
phase
deep
understand
metabol
switch
mechan
would
help
explor
key
metabol
checkpoint
novel
target
futur
therapeut
intervent
epidemiolog
control
chaga
diseas
use
omic
approach
silico
metabol
network
construct
use
identifi
metabol
gap
block
reaction
differenti
host
parasit
metabol
may
exploit
drug
therapi
brauer
et
al
breitl
et
al
kafsack
llina
kalisiak
et
al
may
et
al
metabol
network
analysi
use
identifi
promis
target
therapeut
import
leishmania
infantum
chavali
et
al
cruzi
epimastigot
robert
et
al
plasmodium
falciparum
fatumo
et
al
yeh
et
al
current
due
lack
kinet
paramet
genom
scale
metabol
model
gem
use
concept
flux
balanc
analysi
obrien
et
al
also
becom
popular
among
research
applic
gem
alreadi
appli
map
effect
chloroquin
plasmodium
falciparum
tewari
et
al
predict
dosedepend
inhibit
dna
replic
drugsensit
drugresist
p
falciparum
strain
silico
gene
knockout
gem
leishmania
infantum
leishmania
donovani
sharma
et
al
subramanian
sarkar
predict
trypanothion
reductas
tryr
gene
essenti
neglig
sequenc
ident
human
protein
comparison
stage
specif
flux
distribut
promastigot
amastigot
stage
illustr
differ
metabol
environment
condit
fluxbal
analysi
fba
p
falciparum
metabol
network
abl
reproduc
experiment
geneknockout
phenotyp
drug
inhibit
assay
accuraci
plata
et
al
identifi
thioredoxin
reductas
lethal
redox
system
biolog
artemisinin
resist
sensit
blood
stage
p
falciparum
shown
import
mitochondri
function
glutathion
redox
system
surviv
artemisinin
stress
chen
et
al
peatey
et
al
carey
et
al
likewis
kinet
model
trypanothion
synthas
tri
tryr
trypanosoma
brucei
formul
model
abl
conclud
tri
activ
tightli
regul
leroux
et
al
olinsandov
et
al
due
increas
appear
resist
clinic
isol
mani
parasit
decreas
efficaci
current
chemotherapi
issu
concern
urgent
need
develop
altern
agent
new
mode
action
requir
tradit
small
organ
molecul
target
small
caviti
target
protein
inhibit
specif
catalyt
center
bind
site
natur
substrat
analog
drew
proteinprotein
interact
network
provid
insight
drug
target
toward
disrupt
proteinprotein
interact
classic
small
molecul
alway
ideal
suit
fri
gem
also
explor
find
new
drug
target
combat
antimicrobi
resist
mani
bacteria
gem
develop
integr
gene
express
data
metabol
pathway
studi
effect
ribosom
target
antibiot
metabol
pseudomona
aeruginosa
abl
spot
import
reaction
flux
correl
gene
activ
level
xu
et
al
metabol
simul
anoth
highqual
model
pseudomona
aeruginosa
show
mechan
polymyxin
resist
polymixin
exert
remark
chang
physiochem
properti
outer
membran
zhu
et
al
similar
model
studi
antibiot
treatment
respons
develop
multidrug
resist
bacteria
includ
acinetobact
baumannii
presta
et
al
mycobacterium
tuberculosi
colijn
et
al
yersinia
pesti
navid
almaa
mathemat
model
appli
model
kinet
bacteri
growth
gene
transfer
antibiot
resist
knopoff
anchez
san
kinet
model
gene
transfer
motil
nonmotil
azotobact
vinelandii
effect
depict
experiment
determin
rate
tetracyclin
resist
gene
transform
abl
explain
relationship
transform
frequenc
vari
dna
cell
concentr
lu
et
al
system
biolog
also
offer
possibl
method
screen
novel
target
method
combat
antibacteri
resist
synthet
biolog
one
method
becom
method
choic
among
research
gene
circuit
synthet
biolog
provid
new
insight
natur
genenetwork
dynam
lead
identif
new
drug
target
herrera
huang
et
al
walsh
due
increas
popular
system
biolog
fight
antibiot
resist
bacteria
enabl
construct
biolog
system
antibiot
product
involv
complex
multipl
genet
circuit
effici
overexpress
metabolit
enzym
cell
wang
et
al
weber
et
al
past
decad
seen
bloom
technolog
genom
sequenc
time
well
cost
sequenc
data
assembl
reduc
great
pace
week
hour
million
thousand
dollar
respect
accuraci
read
also
increas
time
technolog
evolv
http
illumina
http
www
illuminacom
solid
http
wwwappliedbiosystemscom
helico
heliscop
http
wwwhelicosbiocom
pacif
bioscienc
smrt
http
wwwpacificbiosciencescom
oxford
nanopor
http
wwwnanoporetechcom
gullap
et
al
advanc
made
wg
access
routin
use
vast
divers
applic
wg
one
import
focu
util
case
antimicrobi
resist
main
criteria
classifi
microb
resist
particular
drug
presenceabs
specif
gene
certain
mutat
apart
identif
resist
strain
wg
use
identif
novel
drug
target
web
server
resfind
develop
identifi
acquir
antimicrobi
resist
gene
bacteria
use
wg
data
zankari
et
al
server
still
limit
detect
resist
gene
obtain
horizont
transfer
mutat
provid
complet
inform
wg
use
keep
check
spread
pathogen
henc
control
infect
diagnos
resist
strain
earli
stage
infect
help
decid
drug
regimen
infect
specif
strain
thu
minim
unnecessari
drug
exposur
resist
strain
great
use
clinic
give
earli
warn
emerg
drug
resist
research
wg
provid
great
scope
understand
mechan
respons
resist
look
variou
genom
aspect
play
key
role
resist
develop
limit
analyz
interpret
vast
data
gener
sequenc
oser
et
al
zankari
et
al
decad
long
battl
microb
drug
seem
like
microb
evolv
superbug
defeat
human
develop
variou
mechan
keep
antimicrobi
far
away
amongst
vast
mechan
studi
target
involv
efflux
pump
microb
exhibit
resist
drug
either
overexpress
efflux
pump
henc
caus
increas
efflux
case
may
enhanc
activ
efflux
pump
either
mutat
gene
caus
alloster
chang
whatev
mechan
end
result
less
accumul
drug
insid
microb
need
hour
find
new
strategi
make
super
bug
suscept
drug
doabl
method
target
efflux
pump
minim
pump
express
decreas
affin
drug
bind
directli
inhibit
pump
activ
mani
research
group
contribut
develop
epi
amp
exist
antimicrobi
agent
reus
base
combinatori
therapi
reason
failur
invivo
clinic
trial
mostli
potenti
antimicrobi
agent
test
laboratori
gener
resist
strain
focu
test
resist
isol
patient
sampl
decreas
failur
rate
clinic
trial
addit
effort
must
made
design
epi
rather
small
peptid
would
specif
target
efflux
pump
particular
type
microb
specif
small
peptid
may
design
either
inhibit
pump
alloster
modul
therebi
decreas
activ
peptid
act
alloster
specif
pump
minim
possibl
resist
instead
contribut
mostli
make
microb
suscept
exist
antimicrobi
agent
target
redox
metabol
pathway
microb
use
system
genom
approach
serv
anoth
strategi
discuss
approach
may
help
avoid
drug
toler
well
efflux
pump
mediat
resist
current
research
scenario
open
vast
scope
identifi
new
antimicrobi
repurpos
exist
one
efficaci
enhanc
combinatori
therapi
author
think
utmost
import
focu
erad
revers
drug
resist
lest
come
futur
everi
exist
antimicrobi
drug
wast
target
specif
efflux
pump
well
find
critic
import
protein
necessari
microb
surviv
system
genom
approach
sure
provid
us
way
minim
occurr
resist
author
declar
conflict
interest
